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Question
The cryopyrin-associated periodic syndromes (CAPS) are
characterized by recurrent episodes of systemic inflam-
mation. CAPS is caused by mutations in the NLRP3 gene
encoding cryopyrin, an important component of the
NLRP3 inflammasome that activates caspase-1 resulting
in inflammation by excessive production of IL-1b and
others. Besides confirmed pathogenic NLRP3 mutations,
patients with CAPS-like symptoms frequently show low
penetrance variants in NLRP3. The disease relevance of
these variants is inconsistent. The analysis of IL-1b in the
serum did not prove to be a valid diagnostic test in these
individuals.
Methods
In this study, we investigated if an inflammasome activa-
tion assay differentiates between patients with confirmed
pathogenic CAPS mutations, patients with low pene-
trance NLRP3 variants (V198M and Q703K) and healthy
controls. The study population consisted of 17 patients
with genetically proven Muckle-Wells syndrome, 11
patients with low penetrance NLRP3 variants and 15
healthy controls. Concentrations of IL-1b, IL-18, Cas-
pase-1, TNF-a and IL-6 were quantified in cell culture
supernatants after inflammasome stimulation with LPS
and LPS + ATP for several time intervals.
Results
The release of mature IL-1b, IL-18, and caspase-1 into
cell culture supernatants after 4h of inflammasome sti-
mulation was significantly increased in patients with
confirmed pathogenic CAPS mutations compared to low
penetrance NLRP3 variants and controls. IL-1b secre-
tion in CAPS patients correlated with disease severity.
TNF-a secretion was significantly reduced in CAPS
patients and NLRP3 variants when compared to healthy
controls after 4h of stimulation.
Conclusion
This inflammasome activation assay differentiates
between autoinflammation patients with confirmed
pathogenic CAPS mutations and patients with low pene-
trance NLRP3 variants, and points towards alternative
pathophysiological mechanisms in low penetrance
NLRP3 variants.
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